IQVIA (NYSE:IQV) Now Covered by Stephens

Stephens initiated coverage on shares of IQVIA (NYSE:IQV) in a research note issued to investors on Friday morning, MarketBeat reports. The firm issued an overweight rating and a $250.00 target price on the medical research company’s stock.

A number of other brokerages also recently issued reports on IQV. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Robert W. Baird cut their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Truist Financial decreased their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Stock Up 3.0 %

Shares of NYSE IQV opened at $197.27 on Friday. The business has a 50-day moving average of $208.90 and a two-hundred day moving average of $223.28. The company has a market capitalization of $35.80 billion, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of IQVIA during the 3rd quarter worth $147,683,000. 1832 Asset Management L.P. boosted its position in shares of IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter worth about $70,610,000. Finally, Impax Asset Management Group plc grew its position in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after purchasing an additional 264,555 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.